G28UCM

G28UCM (also known as UCMG028 or UCM05) is a synthetic polyphenolic small molecule that acts as a dual inhibitor of fatty acid synthase (FASN) and the bacterial cell division protein FtsZ. Developed through a collaboration involving the Universidad Complutense de Madrid and the Universitat de Girona, G28UCM is primarily being investigated as an antineoplastic agent for the treatment of HER2-positive breast cancer, particularly to overcome resistance to standard anti-HER2 therapies like trastuzumab and lapatinib. By inhibiting FASN, G28UCM disrupts lipid raft formation, leading to the downregulation of HER2, AKT, and ERK1/2 signaling pathways and inducing apoptosis in cancer cells. Additionally, G28UCM exhibits antibacterial activity against Gram-positive bacteria by binding to the GTP-binding site of FtsZ and disrupting Z-ring formation, as well as antiviral activity against HSV-1 and HSV-2.

Other names

1,3-bis((3,4,5-trihydroxybenzoyl)oxy)naphthalene3-(3,4,5-trihydroxybenzoyloxy)naphthalen-1-yl 3,4,5-trihydroxybenzoate3,4,5-trihydroxy-benzoic acid 1,1'-(1,3-naphthalenediyl) ester